Review of the field
Two decades of research into the nature of progressive kidney disease have highlighted the role of fibrosis-that is, glomerular and tubulointerstitial scarring-as a common endpoint of almost all forms of renal damage [1, 2] . While much is known about the molecular background of fibrosis and the growth factors and cytokines that prompt fibroblasts or transdifferentiated kidney cells to release collagen and matrix components [3, 4] , the search for a single 'master switch' that initiates the process remains elusive. This would be extremely important, as targeting this key factor or signal would enable us to 'turn off' fibrosis and perhaps the progressive loss of renal function that plagues millions of individuals worldwide [5] .
The paper by Grgic establishes a link between fibrosis and transmembrane ion fluxes, namely K + and Ca (Tables 1 and 2 ). These channels regulate K + outflow, increasing the driving force for Ca 2+ entry through hyperpolarization of the plasma membrane [6] . In K Ca 3.1, four identical subunits associate to form a symmetric homotetramer. Each subunit has six hydrophobic alpha helical domains which insert into the cell membrane. A five-residue loop between the fifth and sixth transmembrane domain forms the K + selectivity filter. In addition, SK potassium channels are tightly associated with the protein calmodulin, which accounts for the Ca 2+ sensitivity of these channels, usually activated by [Ca 2+ ] i slightly below 1 µM. It has long been known that K Ca 3.1-mediated Ca 2+ influx is associated with vascular inflammation, atherogenesis and proliferation of endothelial cells, T lymphocytes, macrophages, vascular smooth muscle cells, fibroblasts etc. [7] [8] [9] [10] [11] . Cell proliferation is believed to follow K + efflux and Ca 2+ entry as a result of Ca 2+ -dependent growth factor gene expression, along with activation of cyclins and kinases involved in cell division. K + channel activity seems required for the G 1 -S transition. On the other hand, proliferation is limited by enhanced apoptosis, resulting from cell shrinkage upon K + efflux (apoptotic volume decrease), and by activation of caspases, directly inhibited by cytosolic K + . K Ca 3.1 have also been implicated in transcellular chloride secretion and cyst growth in autosomal-dominant polycystic kidney disease [12] . The investigators herein provide multiple lines of evidence that K Ca 3.1 critically control renal scarring. First, mitogens upregulate the channel (which has weak baseline activity) in murine renal fibroblasts. Second, TRAM-34 
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Boldface, small-conductance K + channels; GPCR, G-protein-coupled receptors. blocks bFGF-stimulated proliferation of these cells. Third, mouse unilateral ureteral obstruction (UUO), a classical model of renal fibrosis [13] , is associated with increased K Ca 3.1 gene expression. Fourth, K Ca 3.1 KO mice fail to develop fibrosis in response to UUO. Finally, TRAM-34 similarly blocks fibrosis in UUO mice. This is a neat experimental approach, as often seen in previous years for growth factors and cytokines implicated in kidney fibrosis such as transforming growth factor-β1 [14] , bone morphogenic protein-1 [15] , platelet-derived growth factor [16] and hepatocyte growth factor-1 [17] , among others. However, the 'fibrosis master switch' model has its drawbacks. First is its uniqueness. A review by Boor et al. identified in 2007 some 17 target mechanisms of kidney fibrosis, successfully counteracted by no less than 80 different experimental approaches, including blocking Abs, inhibitors and receptor antagonists [5] . The likelihood of a 'one-fitsall' mechanism is low, based on current understanding of the complexity of tissue healing through fibroblast activation [18] . Second, blocking fibrosis may not be enough to rescue a kidney from progressive failure. 'True repair' would also involve regeneration of specialized cells and reshaping structures that have been lost. Terminal differentiation of the adult kidney seems to be the major obstacle to regenerative medicine [19] .
Third, even though fibrosis may well be triggered by overwork of surviving intact nephrons, most data point to a key role of the initial renal injury, which progressively extends over time to the residual nephrons. Damage to the filtration barrier in diabetic glomerulopathy or experimental glomerulonephritis, for example, is an ongoing process, further amplified by tubular overload and interstitial inflammation [20] .
Fourth, under most circumstances, fibrosis follows when inflammation subsides. As sustained inflammation accompanies most forms of renal injury [20] , cutting off the deposition of collagen would leave untouched the primary process that yields nephron loss over months to years in the human kidney. Interestingly, no differences in mononuclear cell infiltration were noted in K Ca 3.1 − / − mice, in comparison with their UUO wild-type littermates.
Finally, murine models of fibrosis suffer from the strong tendency of this species to heal lesions through scarring. The kidney of higher mammalians has a much longer lifespan and a definitely slower rate of collagen fiber deposition. Inhibition of K Ca 3.1 would have to last for years to ward off fibrosis in chronic diseases such as pyelonephritis or diabetic nephropathy, with unknown effects on excitable tissue and extrarenal organs expressing this channel.
What is in it for the practicing nephrologist
The time has not yet come for the practicing nephrologist to directly interfere with the fibrosclerotic evolution of renal disorders [5] . To date, the one and only effective approach to slow down decay of renal function is still renin-angiotensin system (RAS) blockade with angiotensin-converting enzyme inhibitors, ANG II receptor antagonists or perhaps renin inhibitors [5] . Yet, work like this one by Grgic et al. may shed light on some mechanisms of fibrosis that can be soon pharmacologically targeted to delay progression of renal failure. Interestingly, such an approach would possibly bypass the serious adverse effects of RAS inhibitors, including fragile renal haemodynamics, acute worsening of renal function, hyperkalaemia etc. What is still unclear is whether there is a common pathway leading to fibrosis Potassium channels and renal fibrosis 355 independent of the nature of renal injury, or rather that each individual disease leads to scarring of the kidney via different mechanisms [5] . Moreover, we need to know how relevant proteinuria is to tubulointerstitial damage, for example, and whether diabetic nephropathy or a glomerulonephritis with the nephrotic syndrome are equally sensitive to K Ca 3.1 blockade as this non-proteinuric model of UUO. Finally, it is necessary to assess whether, similar to UUO in mice, K Ca 3.1 plays a role in human kidney fibrosis, whether they could be safely inhibited for a certain length of time and then to eventually design a controlled randomized clinical trial with repeated biopsies. We have a long way to go, indeed. In the meantime, our patients will likely have to rely on their renoprotective regimens for a while.
Take-home message
Renal fibrosis can be targeted in experimental animals by manipulation of intermediate/small-conductance K Ca 3.1 channels: a potential step forward in the quest to prevent progressive renal disease.
